Abstract:Abstract Genomic instability is a key hallmark of cancer that arises owing to defects in the DNA damage response (DDR) and/or increased replication stress. These alterations promote the clonal evolution of cancer cells via the accumulation of driver aberrations, including gene copy-number changes, rearrangements, and mutations; however, these same defects also create vulnerabilities that are relatively specific to cancer cells, which could potentially be exploited to increase the therapeutic index of anticancer treatments and thereby improve patient outcomes. The discovery that BRCA-mutant cancer cells are exquisitely sensitive to inhibition of poly(ADP-ribose) polymerase has ushered in a new era of research on biomarker-driven synthetic lethal treatment strategies for different cancers. The therapeutic landscape of antitumor agents targeting the DDR has rapidly expanded to include inhibitors of other key mediators of DNA repair and replication, such as ATM, ATR, CHK1 and CHK2, DNA-PK, POLQ, USP1 and WEE1. Efforts to optimize these therapies are ongoing across a range of cancers, involving the development of predictive biomarker assays of responsiveness (beyond BRCA mutations), assessment of the mechanisms underlying intrinsic and acquired resistance, and evaluation of rational, tolerable combinations with standard-of-care treatments (such as chemotherapeutics and radiation), novel molecularly targeted agents and immune-checkpoint inhibitors. Citation Format: Timothy A. Yap. Latest developments in targeting the DNA damage response in the clinic [abstract]. In: Proceedings of the AACR Special Conference on Ovarian Cancer; 2023 Oct 5-7; Boston, Massachusetts. Philadelphia (PA): AACR; Cancer Res 2024;84(5 Suppl_2):Abstract nr IA010.

Targeting shelterin proteins for cancer therapy

Shaping DNA damage responses: Therapeutic potential of targeting telomeric proteins and DNA repair factors in cancer

Targeting Bromodomain Protein ANCCA/ATAD2 Enhances the Efficacy of DNA‑damaging Chemotherapy Agents and Radiation.

Targeting DNA repair pathways: a novel approach to reduce cancer therapeutic resistance.

Shelterin complex and associated factors at human telomeres

Targeting ATR in patients with cancer

Shelterin-Mediated Telomere Protection

Selective ATM inhibition augments radiation-induced inflammatory signaling and cancer cell death

Ethnicity in the reported pain, emotional distress and requests of medical outpatients.

Shelterin complex in telomere protection: recent insights and pathological significance

Targeting DNA damage response pathways in cancer

Abstract IA010: Latest developments in targeting the DNA damage response in the clinic

The Altered Functions of Shelterin Components in ALT Cells

Set systems with three intersections

Alterations in fibrinogen, plasminogen, and inhibitors of plasmin with the growth of V2 carcinoma in rabbits.

Ionic conducting lanthanide oxides.

Design, synthesis, and biological characterization of proteolysis targeting chimera (PROTACs) for the Ataxia telangiectasia and RAD3-related (ATR) kinase

Recent advances in DDR (DNA damage response) inhibitors for cancer therapy

Small Molecular Inhibitors That Target ATM for Drug Discovery: Current Research and Potential Prospective

Discovery of novel ataxia telangiectasia mutated (ATM) kinase modulators: Computational simulation, biological evaluation and cancer combinational chemotherapy study

Role of shelterin in cancer and aging